Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations - PubMed (original) (raw)
Multicenter Study
. 2008 Sep 1;68(12):1257-62.
doi: 10.1002/pros.20793.
Bao-Li Chang, Sarah D Isaacs, Kathleen E Wiley, Fredrik Wiklund, Pär Stattin, David Duggan, John D Carpten, Bruce J Trock, Alan W Partin, Patrick C Walsh, Henrik Grönberg, Jianfeng Xu, William B Isaacs, S Lilly Zheng
Affiliations
- PMID: 18491292
- PMCID: PMC2800258
- DOI: 10.1002/pros.20793
Multicenter Study
Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations
Jielin Sun et al. Prostate. 2008.
Abstract
Background: A strong cumulative effect of five genetic variants and family history on prostate cancer risk was recently reported in a Swedish population (CAPS). We carried out this study to confirm the finding in two U.S. study populations and perform a combined analysis to obtain a more stable estimate of the odds ratio (OR) for prostate cancer.
Methods: We evaluated three SNPs at 8q24 and one SNP each at 17q12 and 17q24.3 in two study populations in the U.S. The first was a hospital-based case-control study population at Johns Hopkins Hospital (JHH), including 1,563 prostate cancer patients and 576 control subjects. The second was the National Cancer Institute Cancer Genetic Markers of Susceptibility (CGEMS) Initiative, including 1,172 prostate cancer patients and 1,157 control subjects.
Results: We confirmed a cumulative effect of five risk variants on prostate cancer risk. Based on a total of 5,628 cases and 3,514 controls from JHH, CGEMS, and CAPS, men who carry any combination of 1, 2, 3, and 4 or more of these five risk variants have an estimated OR (95% CI) of 1.41 (1.20-1.67), 1.88 (1.59-2.22), 2.36 (1.95-2.85), and 3.80 (2.77-5.22) for prostate cancer, respectively, compared to men who do not have any of these five risk variants. When family history was included, the cumulative effect was stronger.
Discussion: These results provide an important confirmation for the cumulative effect of five genetic risk variants on prostate cancer risk. The more stable OR estimates of the cumulative effect of these six risk factors are a major step toward individual risk characterization for this disease.
(c) 2008 Wiley-Liss, Inc.
Figures
Similar articles
- Clinical utility of five genetic variants for predicting prostate cancer risk and mortality.
Salinas CA, Koopmeiners JS, Kwon EM, FitzGerald L, Lin DW, Ostrander EA, Feng Z, Stanford JL. Salinas CA, et al. Prostate. 2009 Mar 1;69(4):363-72. doi: 10.1002/pros.20887. Prostate. 2009. PMID: 19058137 Free PMC article. - Cumulative association of five genetic variants with prostate cancer.
Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, Adami HO, Hsu FC, Zhu Y, Bälter K, Kader AK, Turner AR, Liu W, Bleecker ER, Meyers DA, Duggan D, Carpten JD, Chang BL, Isaacs WB, Xu J, Grönberg H. Zheng SL, et al. N Engl J Med. 2008 Feb 28;358(9):910-9. doi: 10.1056/NEJMoa075819. Epub 2008 Jan 16. N Engl J Med. 2008. PMID: 18199855 - A replication study examining three common single-nucleotide polymorphisms and the risk of prostate cancer in a Japanese population.
Liu M, Suzuki M, Arai T, Sawabe M, Enomoto Y, Nishimatsu H, Kume H, Homma Y, Kitamura T. Liu M, et al. Prostate. 2011 Jul;71(10):1023-32. doi: 10.1002/pros.21317. Epub 2010 Dec 28. Prostate. 2011. PMID: 21557267 - 8q24 rs4242382 polymorphism is a risk factor for prostate cancer among multi-ethnic populations: evidence from clinical detection in China and a meta-analysis.
Zhao CX, Liu M, Xu Y, Yang K, Wei D, Shi XH, Yang F, Zhang YG, Wang X, Liang SY, Zhao F, Zhang YR, Wang NN, Chen X, Sun L, Zhu XQ, Yuan HP, Zhu L, Yang YG, Tang L, Jiao HY, Huo ZH, Wang JY, Yang Z. Zhao CX, et al. Asian Pac J Cancer Prev. 2014;15(19):8311-7. doi: 10.7314/apjcp.2014.15.19.8311. Asian Pac J Cancer Prev. 2014. PMID: 25339022 Review. - A systematic review of replication studies of prostate cancer susceptibility genetic variants in high-risk men originally identified from genome-wide association studies.
Ishak MB, Giri VN. Ishak MB, et al. Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1599-610. doi: 10.1158/1055-9965.EPI-11-0312. Epub 2011 Jun 29. Cancer Epidemiol Biomarkers Prev. 2011. PMID: 21715604 Review.
Cited by
- Clinical validity and utility of genetic risk scores in prostate cancer.
Helfand BT, Kearns J, Conran C, Xu J. Helfand BT, et al. Asian J Androl. 2016 Jul-Aug;18(4):509-14. doi: 10.4103/1008-682X.182981. Asian J Androl. 2016. PMID: 27297129 Free PMC article. Review. - Associations of ChREBP and Global DNA Methylation with Genetic and Environmental Factors in Chinese Healthy Adults.
Gao J, Qiu X, Wang X, Peng C, Zheng F. Gao J, et al. PLoS One. 2016 Jun 9;11(6):e0157128. doi: 10.1371/journal.pone.0157128. eCollection 2016. PLoS One. 2016. PMID: 27281235 Free PMC article. - Multigene panels in prostate cancer risk assessment: a systematic review.
Little J, Wilson B, Carter R, Walker K, Santaguida P, Tomiak E, Beyene J, Usman Ali M, Raina P. Little J, et al. Genet Med. 2016 Jun;18(6):535-44. doi: 10.1038/gim.2015.125. Epub 2015 Oct 1. Genet Med. 2016. PMID: 26426883 Review. - Associations Between iCOGS Single Nucleotide Polymorphisms and Upgrading in Both Surgical and Active Surveillance Cohorts of Men with Prostate Cancer.
Kearns JT, Lapin B, Wang E, Roehl KA, Cooper P, Catalona WJ, Helfand BT. Kearns JT, et al. Eur Urol. 2016 Feb;69(2):223-8. doi: 10.1016/j.eururo.2015.09.004. Epub 2015 Sep 26. Eur Urol. 2016. PMID: 26411806 Free PMC article. - Prostate cancer in young men: an important clinical entity.
Salinas CA, Tsodikov A, Ishak-Howard M, Cooney KA. Salinas CA, et al. Nat Rev Urol. 2014 Jun;11(6):317-23. doi: 10.1038/nrurol.2014.91. Epub 2014 May 13. Nat Rev Urol. 2014. PMID: 24818853 Free PMC article. Review.
References
- Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, Adami HO, Hsu FC, Zhu Y, Bälter K, Kader AK, Turner AR, Liu W, Bleecker ER, Meyers DA, Duggan D, Carpten JD, Chang BL, Isaacs WB, Xu J, Grönberg H. Cumulative association of five genetic variants with prostate cancer. N Engl J Med. 2008;358(9):910–919. - PubMed
- Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, Sigurdsson A, Benediktsdottir KR, Cazier JB, Sainz J, Jakobsdottir M, Kostic J, Magnusdottir DN, Ghosh S, Agnarsson K, Birgisdottir B, Le Roux L, Olafsdottir A, Blondal T, Andresdottir M, Gretarsdottir OS, Bergthorsson JT, Gudbjartsson D, Gylfason A, Thorleifsson G, Manolescu A, Kristjansson K, Geirsson G, Isaksson H, Douglas J, Johansson JE, Bälter K, Wiklund F, Montie JE, Yu X, Suarez BK, Ober C, Cooney KA, Gronberg H, Catalona WJ, Einarsson GV, Barkardottir RB, Gulcher JR, Kong A, Thorsteinsdottir U, Stefansson K. A common variant associated with prostate cancer in European and African populations. Nat Genet. 2006;38:652–658. - PubMed
- Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A, Rafnar T, Bergthorsson JT, Agnarsson BA, Baker A, Sigurdsson A, Benediktsdottir KR, Jakobsdottir M, Xu J, Blondal T, Kostic J, Sun J, Ghosh S, Stacey SN, Mouy M, Saemundsdottir J, Backman VM, Kristjansson K, Tres A, Partin AW, Albers-Akkers MT, Godino-Ivan Marcos J, Walsh PC, Swinkels DW, Navarrete S, Isaacs SD, Aben KK, Graif T, Cashy J, Ruiz-Echarri M, Wiley KE, Suarez BK, Witjes JA, Frigge M, Ober C, Jonsson E, Einarsson GV, Mayordomo JI, Kiemeney LA, Isaacs WB, Catalona WJ, Barkardottir RB, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet. 2007;39:631–637. - PubMed
- Haiman CA, Patterson N, Freedman ML, Myers SR, Pike MC, Waliszewska A, Neubauer J, Tandon A, Schirmer C, McDonald GJ, Greenway SC, Stram DO, Le Marchand L, Kolonel LN, Frasco M, Wong D, Pooler LC, Ardlie K, Oakley-Girvan I, Whittemore AS, Cooney KA, John EM, Ingles SA, Altshuler D, Henderson BE, Reich D. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet. 2007;39:638–644. - PMC - PubMed
- Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichiello MJ, Fearnhead P, Yu K, Chatterjee N, Wang Z, Welch R, Staats BJ, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Gelmann EP, Tucker M, Gerhard DS, Fraumeni JF, Jr, Hoover R, Hunter DJ, Chanock SJ, Thomas G. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet. 2007;39:645–649. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P50 CA058236/CA/NCI NIH HHS/United States
- CA86323/CA/NCI NIH HHS/United States
- P50 CA058236-08S50001/CA/NCI NIH HHS/United States
- U01 CA086323-09/CA/NCI NIH HHS/United States
- R01 CA095052/CA/NCI NIH HHS/United States
- U01 CA086323/CA/NCI NIH HHS/United States
- R01 CA105055/CA/NCI NIH HHS/United States
- R01 CA106523-04/CA/NCI NIH HHS/United States
- R01 CA112517-04/CA/NCI NIH HHS/United States
- CA106523/CA/NCI NIH HHS/United States
- R01 CA106523/CA/NCI NIH HHS/United States
- CA112517/CA/NCI NIH HHS/United States
- CA58236/CA/NCI NIH HHS/United States
- R01 CA112517/CA/NCI NIH HHS/United States
- R01 CA105055-04/CA/NCI NIH HHS/United States
- CA105055/CA/NCI NIH HHS/United States
- CA95052/CA/NCI NIH HHS/United States
- R01 CA095052-04/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous